EDIT241220P7500
- 0.00
- 0.000.00%
Editas Medicine Newsroom
Bank of America Securities Downgrades Editas Medicine (EDIT) to a Sell
Morgan Stanley Maintains Editas Medicine(EDIT.US) With Hold Rating, Cuts Target Price to $4
Morgan Stanley Remains a Hold on Editas Medicine (EDIT)
Evercore Upgrades Editas Medicine(EDIT.US) to Buy Rating, Maintains Target Price $7
A Quick Look at Today's Ratings for Editas Medicine(EDIT.US), With a Forecast Between $5 to $13
Editas Medicine Is Maintained at Equal-Weight by Barclays
Editas Medicine Analyst Ratings
A Quick Look at Today's Ratings for Editas Medicine(EDIT.US), With a Forecast Between $5 to $12
Truist Securities Adjusts Editas Medicine's Price Target to $8 From $12, Keeps Buy Rating
Wells Fargo Maintains Editas Medicine(EDIT.US) With Buy Rating, Announces Target Price $9
Truist Financial Maintains Editas Medicine(EDIT.US) With Buy Rating
Oppenheimer Maintains Editas Medicine(EDIT.US) With Hold Rating, Cuts Target Price to $10
A Quick Look at Today's Ratings for Editas Medicine(EDIT.US), With a Forecast Between $7 to $13
Cautious Hold on Editas Medicine Amid Strategic Shifts and Financial Uncertainties
Editas Medicine Is Maintained at Buy by Chardan Capital
Editas Medicine Analyst Ratings
Buy Rating for Editas Medicine: Promising In Vivo CRISPR Platform and Strategic Growth Potential Amid Speculative Investment
JonesTrading Maintains Editas Medicine(EDIT.US) With Buy Rating, Maintains Target Price $13
Wells Fargo Sticks to Their Buy Rating for Editas Medicine (EDIT)
Leerink Partners Maintains Editas Medicine(EDIT.US) With Hold Rating, Maintains Target Price $8